24/7 Market News Snapshot 14 May, 2025 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals, Ltd. has recently caught the attention of investors with its impressive pre-market performance, trading at $10.207, representing a substantial increase of 60.49% from its previous close of $6.360. This surge is underscored by a trading volume of 3.17 million shares, demonstrating significant market interest and potential momentum for the stock. Technical indicators suggest a bullish trend, capturing the interest of investors who are optimistic about Quoin’s future performance as it navigates the evolving market landscape.

In addition to its market activities, Quoin Pharmaceuticals is making strong strides in clinical research with its Pediatric Peeling Skin Syndrome (PSS) study, showcasing promising initial data for its treatment candidate QRX003. The study revealed notable improvements in patients’ skin conditions after 12 weeks, as assessed by several key metrics, including the Modified Ichthyosis Area Severity Index (M-IASI), Investigator’s Global Assessment (IGA), and Children’s Dermatology Life Quality Index (CDQLI). Specifically, M-IASI scores decreased significantly from 36 at baseline to 12, while the IGA assessment indicated a shift from severe to mild disease classification. Furthermore, CDQLI scores improved, highlighting QRX003’s positive impact on the quality of life for young patients.

Dr. Michael Myers, CEO of Quoin Pharmaceuticals, remarked on the encouraging results, emphasizing QRX003’s potential to revolutionize the treatment landscape for PSS, a condition presently devoid of approved therapies. The patient will continue receiving treatment, with further assessments set for the 24-week mark, as Quoin aims to widen its study to include more pediatric cases globally. The company remains steadfast in its mission to address unmet medical needs in rare diseases, bolstered by an innovative pipeline that positions it as a frontrunner in the specialty pharmaceutical sector.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.